Indoco Remedies Limited has informed the Exchange that Board of Directors at its meeting held on May 07, 2026, recommended Final Dividend of Rs. 0.20 per equity share.
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts more than Nifty Microcap 250 and 6.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies reported FY2026 consolidated revenue of Rs. 1,79,294 lakhs, up 9.2% from Rs. 1,64,129 lakhs in FY2025, driven by growth in export markets (Rs. 66,882 lakhs vs Rs. 55,090 lakhs). However, the company reported a consolidated net loss of Rs. 9,870 lakhs versus Rs. 7,795 lakhs loss in the prior year, with standalone PAT also negative at Rs. 566 lakhs. Finance costs nearly doubled to Rs. 12,225 lakhs. The auditors issued an unmodified opinion but included an Emphasis of Matter regarding FPP Holding LLC subsidiary, which has negative net worth of Rs. 8,225 lakhs and net loss of Rs. 2,365 lakhs, raising going concern doubts. Exceptional items included trademark license income (Rs. 346 lakhs), loss on sale-leaseback (Rs. 213 lakhs), and New Labour Code impact (Rs. 427 lakhs). The Board recommended a dividend of Rs. 0.20 per share (10%) subject to shareholder approval.
Despite modest revenue growth, the company is loss-making at both standalone and consolidated levels with high debt and negative equity. The auditors' going concern warning on the FPP subsidiary adds risk. Declaring a dividend while burning cash may provide short-term shareholder comfort but raises questions about capital allocation.